{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T02:36:32Z","timestamp":1776479792260,"version":"3.51.2"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.msard.2022.104015","type":"journal-article","created":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T09:46:30Z","timestamp":1656841590000},"page":"104015","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3486-3448","authenticated-orcid":false,"given":"H","family":"Hammer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kamber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Pistor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Diem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Friedli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Hoepner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.msard.2022.104015_bib0004","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1177\/1352458520988637","article-title":"Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): age is a key contributor to presentation","volume":"27","author":"Dahlke","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2022.104015_bib0002","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/bcp.14658","article-title":"Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO","volume":"87","author":"Gibiansky","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.msard.2022.104015_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0122686","article-title":"Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS","volume":"10","author":"Ribbons","year":"2015","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.msard.2022.104015_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1212\/NXI.0000000000000215","article-title":"Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy","volume":"3","author":"Rust","year":"2016","journal-title":"Neurol. Neuroimmunol. NeuroInflamm."},{"key":"10.1016\/j.msard.2022.104015_bib0008","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/j.msard.2020.102019","article-title":"Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases","volume":"41","author":"Rigal","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104015_bib0007","doi-asserted-by":"crossref","unstructured":"Salmon J.H., Cacoub P., Combe B., et\u00a0al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open. 2015;1(1):3\u20137. doi:10.1136\/rmdopen-2014-000034.","DOI":"10.1136\/rmdopen-2014-000034"},{"key":"10.1016\/j.msard.2022.104015_bib0001","unstructured":"U.S. Food and Drug Administration (FDA). Summary of medical product characteristics \u201cOCREVUS\u201d TM (ocrelizumab), 2017 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761053lbl.pdf, last accessed on 04.07.2022."},{"key":"10.1016\/j.msard.2022.104015_bib0011","unstructured":"U.S. Food and Drug Administration (FDA). Fda adverse event reporting system, 2021. Available: https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard (Accessed 12 Apr 21)."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:48Z","timestamp":1761901368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":8,"alternative-id":["S2211034822005247"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104015","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104015"}}